Immuron Ltd has released a press release.
Travelan FY19 Update and Expansion into North America
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Form F-3
- Immuron Receives $1.19M R&D Tax Concession Refund
- IMC Appoints Experienced US Based Biotech Executive as CEO
- NASH clinical trial presentation & continued revenue growth
- US DoD Report Travelan Protects Against Shigella in Primates
Later from Immuron
- Company Update on CDI Clinical Trial and New Strategic Focus
- Immuron Aims to Secure FDA Approval for IMM-124E
- Immuron sales surge by 66% in the Third Quarter of FY19
- Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
- Trading halt
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron